Semaglutide-associated bullous pemphigoid

Clayton P Burruss; Jordan M Jones; Jyoti B Burruss

doi:10.1016/j.jdcr.2021.07.027

Semaglutide-associated bullous pemphigoid

JAAD Case Rep. 2021 Aug 5:15:107-109. doi: 10.1016/j.jdcr.2021.07.027. eCollection 2021 Sep.

Authors

Clayton P Burruss¹, Jordan M Jones², Jyoti B Burruss²

Affiliations

¹ University of Kentucky College of Medicine, Lexington, Kentucky.
² University of Louisville, Department of Medicine, Division of Dermatology, Louisville, Kentucky.

No abstract available

Keywords: BP, bullous pemphigoid; DABP, drug-associated bullous pemphigoid; DPP-4is, dipeptidyl peptidase-4 inhibitors; ELISA, enzyme-linked immunosorbent assay; GLP-1, glucagon-like peptide-1; IIF, indirect immunofluorescence; IgG, immunoglobulin G; diabetes mellitus; drug interactions; glucagon-like peptide-1; pemphigoid; semaglutide.

Publication types

Case Reports